Methodologic Issues When Estimating Risks in Pharmacoepidemiology.

Autor: Edwards JK; Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA., Hester LL; Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA., Gokhale M; Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.; Epidemiology, Real World Evidence, GlaxoSmithKline, Collegeville, PA, USA., Lesko CR; Department of Epidemiology, Johns Hopkins School of Public Health, Baltimore, MD, USA.
Jazyk: angličtina
Zdroj: Current epidemiology reports [Curr Epidemiol Rep] 2016 Dec; Vol. 3 (4), pp. 285-296. Date of Electronic Publication: 2016 Sep 13.
DOI: 10.1007/s40471-016-0089-1
Abstrakt: Risk is an important parameter to describe the occurrence of health outcomes over time. However, many outcomes of interest in healthcare settings, such as disease incidence, treatment initiation, and cause-specific mortality, may be precluded from occurring by other events, often referred to as competing events. Here, we review straightforward approaches to estimate risk in the presence of competing events. We illustrate the application of these methods using timely examples in pharmacoepidemiologic research and compare results to those obtained using analytic simplifications commonly used to handle competing events. These examples demonstrate how the analytic methods used to account for competing events affect the interpretation of results from pharmacoepidemiologic studies.
Competing Interests: Conflict of Interest Mugdha Gokhale is an employee of GlaxoSmithKline. Laure Hester, Catherine Lesko and Jessie Edwards declare that they have no conflicts of interest.
Databáze: MEDLINE